Gut bacteria and your genes: a new clue in Alzheimer's puzzle?

NCT ID NCT05905822

Completed Knowledge-focused Sponsor: University of East Anglia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from the University of East Anglia looked at how gut bacteria break down certain plant compounds (flavan-3-ols) in people with different versions of the APOE gene, which is linked to Alzheimer's risk. 49 healthy adults donated stool and saliva samples. The goal was to see if gene type affects how gut microbes process these compounds, which could help explain why some people are more at risk for Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dietary plant extracts (flavan-3-ols)
What this could lead to: If successful, this could point toward personalized dietary recommendations to reduce Alzheimer's risk based on a person's genes and gut bacteria.
What could go wrong: This is a small, completed lab study using stool samples, not a treatment trial. It only looks at how bacteria process compounds, not whether those compounds prevent or treat Alzheimer's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Norwich and Norfolk University Hospital Clinical Research Facility

Norwich, Norfolk, NR4 7UY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.